Patents by Inventor Michael A. Morin

Michael A. Morin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable polymorph of N-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
    Publication number: 20050090500
    Abstract: The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
    Type: Application
    Filed: November 18, 2004
    Publication date: April 28, 2005
    Inventors: Timothy Norris, Jeffrey Raggon, Richard Connell, James Moyer, Michael Morin, Shama Kajiji, Barbara Foster, Karen Ferrante, Sandra Silberman
  • sPLA2 inhibitors
    Patent number: 6872743
    Abstract: A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 29, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • Cyclohept'b!indole derivatives as spla2 inhibitors
    Publication number: 20040198801
    Abstract: 1
    Type: Application
    Filed: January 15, 2004
    Publication date: October 7, 2004
    Inventors: Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Daniel Jon Sall, Jason Scott Sawyer
  • Compounds and methods for inhibition of HIV and related viruses
    Publication number: 20040116418
    Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
    Type: Application
    Filed: December 1, 2003
    Publication date: June 17, 2004
    Applicant: Medivir AB
    Inventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky
  • Novel spla2 inhibitors
    Publication number: 20040092543
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: May 13, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin Jr, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6730694
    Abstract: A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, John Michael Morin, Jr., Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040077704
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 22, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063967
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20040063941
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock
    Type: Application
    Filed: June 16, 2003
    Publication date: April 1, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • spla2 inhibitors
    Patent number: 6713505
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Substituted tricyclics
    Patent number: 6713645
    Abstract: A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Susan Elizabeth Draheim, Robert Delane Dillard, Edward David Mihelich, Jason Scott Sawyer, Douglas Wade Beight, Michael LeRoy Phillips, Tulio Suarez, Daniel Jon Sall, Jolie Anne Bastian, Michael Lyle Denney, Gary Alan Hite, Michael Dean Kinnick, Robert Theodore Vasileff, John Michael Morin, Jr., Ho-Shen Lin, Michael Enrico Richett, Richard Waltz Harper, John McNeill McGill, III, Benjamin Alan Anderson, Nancy Kay Harn, Richard James Loncharich, Richard Walter Schevitz
  • Spla2 inhibitors
    Publication number: 20040059130
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Novel spla2 inhibitors
    Publication number: 20030236232
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Glycoprotein IIb/IIIa antagonists
    Publication number: 20030135045
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: October 28, 2002
    Publication date: July 17, 2003
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, John Michael Morin, Daniel J. Sall, Marshall A. Skelton, Robert Theodore Vasileff
  • Glycoprotein llb/llla antagonists
    Publication number: 20030130342
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: September 9, 2002
    Publication date: July 10, 2003
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Glycoprotein IIB/IIIA antagonists
    Patent number: 6472405
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: October 29, 2002
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, John Michael Morin, Jr., Daniel J. Sall, Marshall A. Skelton, Robert Theodore Vasileff
  • Compounds and methods for inhibition of HIV and related viruses
    Publication number: 20020132794
    Abstract: The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.
    Type: Application
    Filed: February 13, 2002
    Publication date: September 19, 2002
    Applicant: MEDIVIR AB
    Inventors: Peter Thomas Lind, Rolf Noreen, John Michael Morin, Robert John Ternansky
  • Glycoprotein IIb/IIIa antagonists
    Patent number: 6448269
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: September 10, 2002
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Rühter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Disposable test devices for performing nucleic acid amplification reactions
    Patent number: 6410275
    Abstract: A unit dose test device for a nucleic acid amplification reaction has the form of a elongate disposable test strip. The test strip includes a dual-chamber reaction vessel pre-loaded with nucleic acid amplification reaction reagents, and a plurality of wells for processing a reaction occurring in the reaction vessel.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: June 25, 2002
    Assignee: bioMerieux, Inc.
    Inventors: Bryan Kluttz, Lawrence Burg, Garry Tegeler, Louis Graziano, Christopher Cotter, Michel Guy, James Greer, Geoff McKinley, Luigi Catanzariti, Robert Glassfold, James Clement Bishop, Bruno Colin, Cécile Paris, Thomas Wang, Michael Morin
  • Oxime amide indole type sPLA2 inhibitors
    Patent number: 6391908
    Abstract: A class of novel oxime indoles is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 21, 2002
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Richard Waltz Harper, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett